Cargando…
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways
Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers. However, its efficacy in esophageal cancer remains unclear. In this study, we found that the high expression of HDAC6 was associated with poor...
Autores principales: | Cao, Jinlin, Lv, Wang, Wang, Luming, Xu, Jinming, Yuan, Ping, Huang, Sha, He, Zhehao, Hu, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062526/ https://www.ncbi.nlm.nih.gov/pubmed/30050135 http://dx.doi.org/10.1038/s41419-018-0788-2 |
Ejemplares similares
-
Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
por: Li, Jianglei, et al.
Publicado: (2022) -
Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice
por: Zhang, Wen-bin, et al.
Publicado: (2019) -
Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases
por: Li, Jianglei, et al.
Publicado: (2022) -
ACY-1215, a HDAC6 inhibitor, decreases the dexamethasone-induced suppression of osteogenesis in MC3T3-E1 cells
por: Wang, Na, et al.
Publicado: (2020) -
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury
por: Lin, Chao-Feng, et al.
Publicado: (2020)